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PROforma guidelines and care pathways:  
performance in trials and future plans 
 
John Fox and Vivek Patkar and Richard Thomson and Elizabeth Black.  
Advanced Computation Laboratory, Cancer Research UK, London WC2A 3PX 
 
 
Abstract.  PROforma is a language for modelling clinical 
processes, along with associated tools and methods for creating 
clinical decision support, care planning, workflow and other 
applications.  Of the applications that have been built using the 
language some have been evaluated in primary healthcare 
settings (drug prescribing, referral of suspected cancer patients, 
genetic risk assessment) and others in specialist care of 
patients, including  breast cancer, leukaemia and management 
of HIV+ patients. Eight of these trials have included 
quantitative evaluations on a variety of measures of quality 
and/or effectiveness of care, and all have shown significant 
positive effects. This paper provides an overview of these 
results and previews the CREDO project, which aims to extend 
the PROforma method from focused decision-support and 
workflow applications to supporting large, multi-disciplinary 





As demands for more and better patient care continue to grow 
the shortcomings of medical services are increasingly 
recognized. To Err is Human, the influential report from the 
US Institute of Medicine [1] focused attention on human 
factors in achieving consistently safe decision-making in 
difficult conditions. Quality and safety are now major issues 
with many governments and agencies pursuing policies to 
improve care at both individual and organizational levels (see 
www.openclinical.org). The difficulties for hard-pressed 
clinicians to deliver consistently high quality, safe care are also 
increasingly well documented. In cancer services, for example, 
the joint report by the UK Commission for Healthcare 
Improvement and Audit Commission on cancer care identifies 
a wide range of challenges to the consistent delivery of 
effective detection, diagnosis and treatment.   
Decision support systems have an important contribution 
to make to this problem. In the systematic review of 100 trials 
of decision support systems by Garg et al [2] 62/97 studies 
demonstrated improved practitioner performance (64%). These 
broke down into 16/21 (76%) for simple reminder systems, 
4/10 (40%) in diagnosis applications, 23/37 (62%) “disease 
management” and 19/29 (66%) drug dosing applications. 
Decision  technologies are now seen as a key resource in the 
delivery of modern, evidence-based clinical services. For 
example the UK has committed £6.7 billion over 6 years as part 
of its modernization program for the National Health Service  
through it National Programme for IT in which the successful 
deployment of decision support is a key strategic objective [3]. 
 The Garg et al review subsumes a range of techniques and 
approaches to improving decision-making. Despite the positive 
overall results of the study this is a problem for the field in that 
if decision support systems are to become generally accepted 
by clinical users we need to rationalize and ideally standardize 
the systems they are asked to use. Without standards it will also 
be difficult to achieve reusability, scalability, interoperability 
and other technical features that are needed to attract wide 
adoption [4].  The PROforma approach to this problem 
proposes a standard, computer executable language and 
interchange format for modeling clinical decisions and 
processes [5]. PROforma shares technical features with other 
proposals (see review by Peleg et al, 2002 [6]; a more recent 
overview of current approaches can be found at 
http://www.openclinical.org/gmmintro.html)  but it is  
distinctive in being grounded in a general model of human 
decision-making and a formal framework for decision-making 
and planning with an associated formal semantics [7, 8]. 
Peleg et al [6] and de Clercq et al [9] have carried out 
independent comparisons of published approaches to modelling 
guidelines and protocols. PROforma appears to be distinctive in 
having formal foundations for the language, notably the 
decision-making framework based on logical arguments rather 
than traditional decision analysis. The constructs of the 
language are principled and, experience suggests, intuitive for 
clinicians. The former characteristic supports the creation of 
reliable and sound applications, the latter helps to ensure that 
healthcare professionals are empowered to oversee application 
development and safe use in practice – neither of which are 
typical of conventional software.  
The language has provided a foundation for a number of 
novel technologies and applications, and this has led to an 
encouraging body of evidence that the general approach has 
clinical value. This evidence is summarized below. The syntax 
and operational semantics of the language have been published 
in the open literature [10] to facilitate its use as an interchange 
format and  to promote reusability of content and 
interoperability of applications and application components 
(see also [4]). Comprehensive application development tools 
are also available.  Experience of their utility has now been 
accumulated with several such tools, including the Tallis 
authoring and web publishing suite which is available for 
research use (see web site at www.acl.icnet.uk/TallisTraining) 
and the commercial Arezzo® system available from InferMed 
Ltd. (www.infermed.com).   
 
 
2. REVIEW OF EVALUATIONS: DECISIONS 
AND GUIDELINES 
 
The first practical application of PROforma was CAPSULE, a 
system for assisting general practitioners in prescribing for 
common conditions [11]. Prescribing is an important 
application for decision support in many clinical areas, because 
of the amount of knowledge clinicians must absorb to stay up 
to date. CAPSULE took in patient data and suggested a short 
list of possible medications, together with the arguments for 
and against the different options. The trial showed potential 
  
substantial improvements in decision accuracy (about 30%), 
improved resource use and faster decision-making.   
LISA is an application for advising on dose adjustment in 
treatment of children with acute lymphoblastic leukaemia. A 
trial of LISA has shown that without decision support clinicians 
deviated from the trial protocol on 37% of occasions but with 
support this dropped to zero, and 35/36 of the clinicians said 
they would use LISA if it were routinely available [12]. Note 
that this trial is indicative rather than definitive since it was run 
on retrospective cases. LISA has now been incorporated into a 
prospective trial led by Cancer Research UK’s Paediatric 
Oncology Unit at the London Hospital and integrated into 
InferMed’s MACRO® clinical trial manager. 
An important area of application of decision support and 
care planning technologies is in clinical genetics. As more 
genetic markers become available, individuals who are 
themselves well but worried they are at risk for a particular 
disease because of family history seek guidance from their 
personal physicians and other non-specialists. Physicians are 
frequently willing to provide advice and support, but they do 
not generally feel they have the expertise to take or analyse a 
complex family history, and the problem of communicating 
risk to patients without statistical understanding is notoriously 
difficult. RAGs was developed to help the general practitioner 
take a family history, assess risk and explain risk factors to 
patients [13]. An application for breast and ovarian cancer risk 
was evaluated with Oxfordshire general practitioners, showing 
that with this support they produce more accurate family trees, 
risk assessments and management decisions [14]. In a 
comparison with other software and paper and pencil RAGs 
was chosen as the preferred tool 91.7% of the time.  
If the initial risk assessment is confirmed by subsequent 
genetic testing then this opens the way to providing a high level 
of individualized care. However, customizing an individual’s 
care is difficult and time-consuming, and it is likely to be 
difficult (and expensive) for busy clinical teams to implement 
personalized patient care plans. REACT is a treatment planning 
tool that provides the ability to personalize care plans taking 
into account individual risk information and patient’s 
individual preferences [15]. A trial of the system to assist in 
care planning in a genetic counseling setting has produced 
encouraging results; 7/8 clinical geneticists were initially 
skeptical about its value but after completing the study in an 
actor-based scenario 7/8 were strongly supportive of its value 
[16]. Note that the trial version of REACT uses PROforma 
concepts of plans and argument based decision-making but 
does not represent the care plan explicitly. Polyphony, an 
experimental version imports PROforma models into the 
REACT planning environment where the planning and 
scheduling capabilities of REACT can be applied to a set of 
PROforma care plans and their interactions. 
The general field of clinical genetics has produced the 
most definitive trial of a PROforma application to date, for 
tailoring drug selection and dose to an individual’s genetic 
profile. The Retrogram® system was developed by InferMed 
for Hoffman la Roche (www.retrogram.org). Retrogram 
advises on the use of anti-retroviral therapy for HIV+ patients 
and is believed to be in use with more than 250 clinicians 
worldwide. The HAVANA multicentre trial [17] has shown 
that availability of genotype information significantly improves 
clinicians’ decision-making as measured by viral load, but with 
Retrogram providing genotype interpretation and decision 
support services the viral loads of many more patients’ were 
reduced to the target level. As genetic profiling becomes 
increasingly important in patient care Retrogram could well be 
an important model for the future. 
The CADMIUM imaging system was an early version of 
our language model in combining conventional image 
processing with automated interpretation of images and 
diagnosis [18]. CADMIUM was evaluated in a study in which 
radiographers with specialist training interpreted screening 
mammograms with and without decision support. The question 
was whether such systems could play a role in, or even 
substitute for consultant radiologists, in routine breast cancer 
screening. The system was designed to identify micro-
calcifications in breast tissue automatically and interpret the 
pattern of calcifications in terms of whether they are likely to 
indicate benign or malignant abnormalities. The study indicated 
that the system significantly increased the rate of correct 
classifications of malignant and benign abnormalities while 
also reducing cancer misses and false positives.  
 
 
3. SUPPORTING WORKFLOWS, COMPLEX 
CARE PATHWAYS 
 
The applications described above, and the great majority of 
published studies of clinical decision-support systems, are 
concerned with supporting a single clinical decision. However, 
many routine clinical procedures involve multiple decisions, 
which are naturally carried out in a particular order dependent 
on the availability of data and test results, completion of 
procedures and conclusions about other decisions. Our current 
work is aimed at looking at whether PROforma can model 
more complex workflows, where decisions are just some of the 
tasks required in the care plan. An example of this is TADS, a 
decision support system for the “Triple Assessment” of patients 
with suspected breast cancer. This typically takes place at a 
“same day” clinic where the aim is to achieve a provisional 
diagnosis and risk assessment of women with breast symptoms. 
Triple assessment includes: 
 
1. Clinical Examination;  
2. Various forms of imaging: (mammography, ultrasound, 
MRI,);  
3. Histo-pathology: Fine needle aspiration or Core needle 
biopsy. 
 
The assessments and decisions from these three activities 
feed in to a final management decision about whether she can 
be discharged or referred to the multidisciplinary team to 
oversee her treatment and follow-up. Figure 1 shows a high 
level representation of the tasks in this workflow, using the 
graphical representation of the Tallis authoring system. Here a 
diamond represents any kind of data acquisition (e.g. filling in 
a data entry form, retrieving information from an electronic 
patient record or capturing data from a medical device such as 
an imaging system).  Decisions are represented as circles. 
There are 4 here: family history and risk assessment; a decision 
about what imaging studies to do if any, what biopsy method if 
any, and the final management decision. Figure 2 shows a 
typical web-browser display of a TADS decision, with the 
arguments for and against the different imaging options and 
links to relevant backing information. 
Twenty four practising breast clinicians from UK 
National Health Service (NHS) hospitals participated in the 
study. A balanced-block crossover experiment was conducted 
using paper cases, followed by a questionnaire study and semi-
structured interviews. At the decision points the clinicians 
made significantly more deviations from guideline 
recommendations without the support of the tool.  
  
Ignoring minor deviations, 16 potentially critical errors arose in 
the no-decision-support arm of the trial compared with just one 
when decision-support was available. Opinions of participating 
clinicians towards the decision support tool became more 





Figure 1: representation of triple assessment workflow. The decision nodes represented 
by circles are embedded at various points in the workflow
 
 
Figure 2: TADS support for the imaging decision after completing medical history and clinical examination tasks. 
The system recommends an ultrasound scan but recommends against mammography and doing nothing. For the decision 
option ‘Do a mammogram of both breasts’, arguments for and against have been expanded. Links are provided to the 




Figure 3: Black’s (2002) agent network for simulating clinical referrals showing the architecture of one agent (inset). The 




To the best of our knowledge, this is the first evaluation 
of a decision support tool that supports multiple interdependent 
decisions in cancer care. The results of this initial trial suggest 
that the system can significantly enhance safety and 
consistency of patient care in breast cancer by promoting 
compliance with best practice. 
Despite their relative complexity workflows like this 
represent only a tiny part of the services that are required for 
managing a complex condition like cancer, and in many cases 
patient care involves many different people in different places 
and with different skills. For this reason we have also begun to 
look at the question of whether PROforma can support 
distributed applications, where each application can be viewed 
as an agent that can cooperate with other PROforma agents. 
Huang et al [20, 21] developed an early demonstration of this 
approach in which each agent was capable of making decisions 
using an early version of the PROforma decision model [22]. 
The technical adequacy of this approach was demonstrated in 
an application for distributed breast cancer. Each agent was 
capable of making decisions based on an argumentation 
approach [22, 23] but possessed different expertise and 
therefore needed to seek assistance in certain circumstances. 
For example a “general practitioner” agent has broad but 
shallow knowledge of the patient while a “cancer specialist” 
agent has deeper but narrower expertise.  
More recently Black [24, 25] has extended this 
framework to investigate the potential value of agents to 
support distributed services by simulating an agent network on 
a realistic medical problem.  Her model consists of three 
general practitioners (GP), two family history clinics and a 
genetics clinic (see figure 3, top left). Simulated patients would 
“present” to their GPs, who would decide whether the patient 
required referral for specialist advice or not. The simulated GP   
could make decisions and enact plans specified as PROfoma 
processes. If the GP’s decision criteria indicated referral, then 
the agent arranges this by sending a message to the appropriate 
referral centre. Depending on the queuing strategy used in the 
simulation the agent may also book a provisional appointment 
for the patient at the genetics clinic. The family history agent 
works in a similar fashion, but it decides whether the patient 
needs referral to the genetics clinic. If not then any provisional 
appointment at the genetics clinic will need to be cancelled. 
Once patients have been seen in the genetics clinic their route 
through the system is complete. 
The purpose of this study was to investigate how a 
number of different agents could interact to implement a 
complex, distributed decision model, and to determine whether 
different referral strategies could affect the performance of the 
agent network. Black considered 4 referral strategies. (1)  
Patients are simply seen in the order they arrive at each centre.  
(2) If the GP decides that the patient needs referring to family 
history, then at the same time they make a provisional 
appointment for the patient at the genetics clinic (two versions), 
and (3) as strategy 2 but appointments at the genetics units can 
be reassigned according to priority made by the family history 







Strategy    Av. time    Av. time     Av. time          total  
   at GP        at family     at genetics      cycles 
    
No     33              101              256          380   
Strategy 
 
Ad hoc     10         53             184       247  
 
1st come,  
1st served   26               85              173         284   
 
Prioritised  
on risk      21             116              193                330   
 
Table 1. Average patient queuing times (in cycles) for 
all patients under all strategies (simulated). 
 
 
4. THE CREDO TRIAL 
 
The CREDO project is intended to build on these results in 
order to seek definitive data on the value of advanced tools for 
decision support, care planning and distributed patient 
management in complex multidisciplinary care. The aims of the 
project are to trial a comprehensive suite of computer services 
to support all phases of care from first presentation and 
diagnosis through treatment and follow-up, and facilitate 
communication and coordination across the multidisciplinary 
team. The first task in this project has been to develop a 
comprehensive service model that would be amenable to 
proformalisation. This model is illustrated schematically in 
figure 4, but is described in detail at the project web site 
(www.acl.icnet.uk/credoweb) where a video that explains the 
project can also be found. The aim of the CREDO trial is to 
address the following questions: 
 
• What is the baseline quality and safety of typical 
decision-making in the management of breast cancer?   
• Can PROforma decision support yield improved 
consistency, quality and safety of clinical decision 
making through the patient journey and what are the most 
promising decision points at which to intervene?   
• Can such services be offered in a form that is acceptable 
to and valued by clinicians? Can they free clinicians from 
administrative and operational burdens, allowing them to 
concentrate on looking after patients? 
• Can such support for clinicians and patients lead to 
improved experience for the cancer patient? 
 
The trials described in the previous sections included a number 
of examples of decision-making in breast cancer, many of 
which form elements of the CREDO care pathway. Our service 
model for breast cancer care suggests that across the whole 
multidisciplinary pathway there are approximately 65 decision 
points where there is potential for errors that could significantly 
impact efficacy of treatment or safety of the patient (note that 
the key step of triple assessment includes just 4 of these 
decisions). It is interesting to note that with such a complex 
pathway if error rates in practice are about 1% on average then 
with 65 decisions taken independently only 50% of women 
would get perfect care on average. If error rates are 5% then 
only 3% of women will get perfectly safe care! Evidence from 
the above studies and other literature, notably the US report To 
Err is Human  suggest that the actual frequency of deviations 
from evidence-based recommendations in routine decision-
making could be considerably higher. 
Figure 4: CREDO service model. Each rounded rectangle is a collection of PROforma services.  
Black arrows = information flow, Red arrows = information flow + transfer of responsibility ("referral") 
 
  
5. SUMMARY AND CONCLUSIONS 
 
In eight studies of PROforma applications where 
quantitative performance data have been obtained, all 
have shown significant positive results on a variety of 
techniques and measures. With the simplest assumption 





pattern has a chance probability of less than 0.004 (0.508  
= 0.0039) which is highly significant statistically.  
Current work is investigating the possibility that 
extended versions of PROforma agents may be able to 
support distributed and multidisciplinary care with 
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